Alder Biopharmaceuticals Inc (NASDAQ:ALDR) on Focus After Report of More Shorts

May 16, 2018 - By Jeanette Kaplan

The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) registered an increase of 2.66% in short interest. ALDR’s total short interest was 11.31 million shares in May as published by FINRA. Its up 2.66% from 11.01 million shares, reported previously. With 882,400 shares average volume, it will take short sellers 13 days to cover their ALDR’s short positions. The short interest to Alder Biopharmaceuticals Inc’s float is 20.05%.

It closed at $15.15 lastly. It is down 46.26% since May 16, 2017 and is downtrending. It has underperformed by 57.81% the S&P500.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $1.03 billion. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Coverage

Among 4 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Alder Biopharmaceuticals has $26.0 highest and $17 lowest target. $21’s average target is 38.61% above currents $15.15 stock price. Alder Biopharmaceuticals had 8 analyst reports since January 2, 2018 according to SRatingsIntel. Canaccord Genuity maintained it with “Buy” rating and $20.0 target in Tuesday, January 30 report. Canaccord Genuity maintained it with “Buy” rating and $20.0 target in Thursday, February 8 report. On Monday, January 8 the stock rating was maintained by RBC Capital Markets with “Buy”. The firm has “Buy” rating given on Friday, January 12 by Canaccord Genuity. BMO Capital Markets maintained Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) on Tuesday, January 2 with “Buy” rating. The company was maintained on Wednesday, May 9 by BMO Capital Markets. As per Monday, January 8, the company rating was maintained by BMO Capital Markets.

More notable recent Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) news were published by: Globenewswire.com which released: “Alder BioPharmaceuticals® Appoints Jeremy Green to its Board of Directors” on April 26, 2018, also Benzinga.com with their article: “Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches” published on April 24, 2018, Streetinsider.com published: “Alder BioPharma (ALDR) Has Positive Read-Through from Eli Lilly’s Cluster Headache Data – RBC” on May 15, 2018. More interesting news about Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) were released by: Globenewswire.com and their article: “Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2018 Financial and Operating Results” published on April 30, 2018 as well as Globenewswire.com‘s news article titled: “Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results” with publication date: May 08, 2018.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: